<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Shi J</submitter><funding>Fundamental Research Funds for the Central Universities</funding><funding>Guangdong Provincial Pearl River Talents Program</funding><funding>National Natural Science Foundation of China</funding><funding>Guangzhou Science and Technology Program key projects</funding><pagination>494-511</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8942439</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>345</volume><pubmed_abstract>Abnormal immune cell functions are commonly related to various diseases, including cancer, autoimmune diseases, and infectious diseases. Messenger RNA (mRNA)-based therapy can regulate the functions of immune cells or assign new functions to immune cells, thereby generating therapeutic immune responses to treat these diseases. However, mRNA is unstable in physiological environments and can hardly enter the cytoplasm of target cells; thus, effective mRNA delivery systems are critical for developing mRNA therapy. The two mRNA vaccines of Pfizer-BioNTech and Moderna have demonstrated that lipid nanoparticles (LNPs) can deliver mRNA into dendritic cells (DCs) to induce immunization against severe acute respiratory syndrome coronavirus 2, which opened the floodgates to the development of mRNA t</pubmed_abstract><journal>Journal of controlled release : official journal of the Controlled Release Society</journal><pubmed_title>Delivery of mRNA for regulating functions of immune cells.</pubmed_title><pmcid>PMC8942439</pmcid><funding_grant_id>32071378</funding_grant_id><funding_grant_id>2017GC010482</funding_grant_id><funding_grant_id>82072048</funding_grant_id><funding_grant_id>81901875</funding_grant_id><funding_grant_id>2017GC010713</funding_grant_id><funding_grant_id>32071380</funding_grant_id><funding_grant_id>52130301</funding_grant_id><funding_grant_id>202103030004</funding_grant_id><pubmed_authors>Du XJ</pubmed_authors><pubmed_authors>Lu ZD</pubmed_authors><pubmed_authors>Shen S</pubmed_authors><pubmed_authors>Xu CF</pubmed_authors><pubmed_authors>Shi J</pubmed_authors><pubmed_authors>Huang MW</pubmed_authors><pubmed_authors>Wang J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Delivery of mRNA for regulating functions of immune cells.</name><description>Abnormal immune cell functions are commonly related to various diseases, including cancer, autoimmune diseases, and infectious diseases. Messenger RNA (mRNA)-based therapy can regulate the functions of immune cells or assign new functions to immune cells, thereby generating therapeutic immune responses to treat these diseases. However, mRNA is unstable in physiological environments and can hardly enter the cytoplasm of target cells; thus, effective mRNA delivery systems are critical for developing mRNA therapy. The two mRNA vaccines of Pfizer-BioNTech and Moderna have demonstrated that lipid nanoparticles (LNPs) can deliver mRNA into dendritic cells (DCs) to induce immunization against severe acute respiratory syndrome coronavirus 2, which opened the floodgates to the development of mRNA t</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May</publication><modification>2025-05-18T12:34:10.942Z</modification><creation>2025-04-04T14:21:29.903Z</creation></dates><accession>S-EPMC8942439</accession><cross_references><pubmed>35337940</pubmed><doi>10.1016/j.jconrel.2022.03.033</doi></cross_references></HashMap>